BMJ Physiotherapy Expands to One@Kentridge Medical Centre Adjacent to NUH
'We built this branch to serve patients who need continuity in care—especially right after surgery or discharge from NUH.'— Bruno Chia, Principal Physiotherapist, BMJ@One@Kentridge
SINGAPORE, CENTRAL SINGAPORE, SINGAPORE, July 20, 2025 / EINPresswire.com / -- Trusted by doctors and patients across the island, BMJ Physiotherapy has quietly opened a new clinic at One@Kentridge Medical Centre, located within the National University Hospital (NUH) compound. The West-side addition, which began operations in April 2025, offers a seamless transition for post-hospital recovery and is led by seasoned physiotherapist Bruno Chia—a name familiar to many in Singapore's healthcare and sports community.
'We built this branch to serve the needs of patients who are discharged from hospital but still need continuity in care,' says Bruno. 'One@Kentridge offers a unique opportunity—we're steps away from NUH wards, yet operate as a private practice. This gives our patients flexibility, comfort, and access to hands-on, specialist-led rehabilitation.'
From NUH to Home: The Missing Link in Recovery While NUH houses its own physiotherapy department, demand for musculoskeletal and post-operative rehab often stretches beyond availability. BMJ Physiotherapy's clinic at One@Kentridge fills this critical gap—providing direct access to physiotherapy within the same compound as the hospital.
Whether it's a senior recovering from joint replacement surgery or a young adult with a slipped disc, BMJ's West Singapore branch is designed to support recovery with minimal downtime, allowing patients to transition from hospital to home without losing treatment momentum.
Located right beside the NUH Main Building (Zone F) and accessible via Kent Ridge MRT, BMJ@One@Kentridge is also ideal for outpatient referrals from NUH doctors, private specialists, and walk-ins seeking expert care.
Google Maps: https://g.co/kgs/1qd4oJH
Leading the Team: Bruno Chia Bruno Chia, Principal Physiotherapist at BMJ@One@Kentridge, brings more than 12 years of experience treating both hospital and private sector patients. A graduate of Trinity College Dublin, he is known for his calm precision, patient-centred approach, and strong communication in English, Mandarin, and Hokkien.
His hospital background at Changi General Hospital (CGH) and Changi Sports Medicine Centre (CSMC) includes accolades such as: - CGH Best Service Award - Eastern Health Alliance Caring Award
He has served as the official physiotherapist at: - South East Asian Games 2015
- World Rugby 7s (2014)
- National Netball Super League
- Singapore Inter-Varsity Taekwondo Championship
Bruno is also a certified Exercise is Medicine Singapore practitioner, RockTape Instructor, and trained in vestibular physiotherapy, helping patients with dizziness, vertigo and balance disorders—an increasingly common condition among the elderly and post-concussive youth.
'Whether it's neck pain or post-op rehabilitation, my goal is to restore confidence in movement. Recovery isn't just physical—it's deeply emotional,' he adds.
A Patient's Words: 'I'm Finally Pain-Free After Months' One of Bruno's patients, Ms Chye Hoon Er, shared this review after being referred by her orthopaedic doctor for lower back issues:
'I had a torn disc (L4 & L5) and was in pain for months. After just a few sessions with Bruno, I could feel the improvement. He took the time to understand my condition and tailor every session to my progress. No generic exercises—only what worked for me. I'm now feeling so much better.'
This personalised care is what BMJ Physiotherapy is best known for. Each case is assessed in detail before any treatment plan is prescribed. Bruno's techniques include Myofascial Release, Muscle Energy Techniques, Joint Mobilisation, and Cognitive Behavioural Approaches—all rooted in evidence-based physiotherapy.
Services Available at BMJ@One@Kentridge - Post-Surgical Rehabilitation (Knee, Hip, Shoulder, Spine) - Vestibular & Balance Therapy (Vertigo, Dizziness) - Sports Injury Treatment & Performance Conditioning - Chronic Pain (Neck, Back, Shoulder) - Scoliosis Management (Children & Adults) - Muscle Weakness & Core Stability Programmes
With immediate appointment availability and no referral letters required, the NUH branch is ideal for patients seeking fast, reliable, and professional physiotherapy care near the hospital.
Serving West Singapore and Beyond Patients from Clementi, Holland, Bukit Timah, Buona Vista and even Jurong East have found the new clinic a welcome alternative to central locations. Its proximity to Kent Ridge MRT and bus lines makes it convenient for both weekday sessions and post-work appointments.
About BMJ Physiotherapy BMJ stands for Bones, Muscles, and Joints—and that's exactly what the team specialises in. Founded by Darek Lam, former Head of Physiotherapy at Changi Hospital, BMJ Physiotherapy is a leading physiotherapy group in Singapore with a team of therapists who are mostly former athletes and experts in manual therapy, injury prevention, and long-term rehab strategies.
BMJ currently operates six branches island wide:
BMJ@ Marine Parade:
1 Marine Parade Central, Parkway Centre, #06-03, Singapore 449408
T: +65 6871 4352 | +65 8127 4395
BMJ@Tampines:
3 Tampines Central 1, Tampines Plaza 1, #06-05, Singapore 529540
T: +65 6871 4350 | +65 9105 6648
BMJ@Ang Mo Kio:
Blk 727 Ang Mo Kio Avenue 6, #01-4254, Singapore 560727
T: +65 6871 4355 | +65 9183 5339
BMJ @Kovan/Hougang:
Blk 204 Hougang St 21, Kovan City, #01-103, Singapore 530204
T:+65 6909 5208 | +65 9181 7290
BMJ @ Kallang Wave Mall
1, Stadium Place, Kallang Wave Mall@Sports Hub. #01-79, Singapore 397628
T: +65 6871 4363 | +65 9101 5338
BMJ@One@Kentridge (NUH):
1 Lower Kent Ridge Road, #04-03/04, One@Kentridge Medical Centre, Singapore 119082
T: +65 6572 4106| +65 8690 3630
Richard Branson
Physio Asia Association
email us here
Visit us on social media:
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Clearbridge Health First Half 2025 Earnings: S$0.08 loss per share (vs S$0.004 loss in 1H 2024)
Clearbridge Health (Catalist:1H3) First Half 2025 Results Key Financial Results Revenue: S$4.92m (up 7.1% from 1H 2024). Net loss: S$1.35m (loss narrowed by 42% from 1H 2024). S$0.08 loss per share. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Clearbridge Health shares are down 33% from a week ago. Risk Analysis Before you take the next step you should know about the 5 warning signs for Clearbridge Health (4 are potentially serious!) that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
20 hours ago
- Yahoo
European drugmakers fall after Trump raises stakes over US drug price cuts
By Ankur Banerjee SINGAPORE (Reuters) -Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping executive order aimed at lowering prices. The letters were the latest setback for a sector still grappling with the prospect of tariffs outlined in the U.S.-EU trade deal that could cost the pharmaceutical industry between $13 billion and $19 billion. Trump called on 17 drugmakers to provide so-called most-favoured-nation prices to every patient enrolled in the government Medicaid health programme for low-income people, and to guarantee such pricing for new drugs. Shares of European drugmakers Sanofi, AstraZeneca, GSK, Merck KGaA and Novo Nordisk slipped between around 1% and 4% in early trading on Friday. Novo's 4% fall extends a selloff this week that started on Tuesday with a 28% plunge, wiping out $70 billion of its market value after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO. The companies were all sent letters by Trump, who gave them until September 29 to respond with binding commitments to those terms. U.S. drugmakers including Pfizer, Johnson & Johnson, Eli Lilly and Merck were also sent the letters. The European healthcare index was down 1.4% by 0731 GMT, its lowest since April. "Trump's directive to the pharma companies will put them on the defensive and adds yet another layer of uncertainty for the sector which could also face import tariffs in time to come," said Vasu Menon, managing director of investment strategy at OCBC. "While Trump has set a deadline for these companies to comply, it remains to be seen if this is hard coded or if he will roll back some of his threats if these companies make an effort to engage him and soften his stance." Analysts, lobbyists and drug pricing experts though said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. The companies including Pfizer, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Trump's executive order in May directed drugmakers to lower medicine prices to align with what other countries pay, leading to some shift in how drugmakers look to sell their medicines. Swiss drugmaker Roche said last week it was considering selling its prescription medicines in the United States directly to consumers to lower costs for patients as part of talks with the U.S. government.
Yahoo
20 hours ago
- Yahoo
European drugmakers fall after Trump raises stakes over US drug price cuts
By Ankur Banerjee SINGAPORE (Reuters) -Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping executive order aimed at lowering prices. The letters were the latest setback for a sector still grappling with the prospect of tariffs outlined in the U.S.-EU trade deal that could cost the pharmaceutical industry between $13 billion and $19 billion. Trump called on 17 drugmakers to provide so-called most-favoured-nation prices to every patient enrolled in the government Medicaid health programme for low-income people, and to guarantee such pricing for new drugs. Shares of European drugmakers Sanofi, AstraZeneca, GSK, Merck KGaA and Novo Nordisk slipped between around 1% and 4% in early trading on Friday. Novo's 4% fall extends a selloff this week that started on Tuesday with a 28% plunge, wiping out $70 billion of its market value after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO. The companies were all sent letters by Trump, who gave them until September 29 to respond with binding commitments to those terms. U.S. drugmakers including Pfizer, Johnson & Johnson, Eli Lilly and Merck were also sent the letters. The European healthcare index was down 1.4% by 0731 GMT, its lowest since April. "Trump's directive to the pharma companies will put them on the defensive and adds yet another layer of uncertainty for the sector which could also face import tariffs in time to come," said Vasu Menon, managing director of investment strategy at OCBC. "While Trump has set a deadline for these companies to comply, it remains to be seen if this is hard coded or if he will roll back some of his threats if these companies make an effort to engage him and soften his stance." Analysts, lobbyists and drug pricing experts though said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. The companies including Pfizer, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Trump's executive order in May directed drugmakers to lower medicine prices to align with what other countries pay, leading to some shift in how drugmakers look to sell their medicines. Swiss drugmaker Roche said last week it was considering selling its prescription medicines in the United States directly to consumers to lower costs for patients as part of talks with the U.S. government. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
